Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2016-07-13 Earnings Release
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 98% confidence The document explicitly states it announces the "unaudited revenue for the second quarter of 2016" and presents an "Income statement" with Q2 2016 and H1 2016 figures. This content structure—presenting key financial highlights for a specific short period (Q2)—is characteristic of an Earnings Release (ER). Although it contains some operational details and a minor capital update, the primary focus is the quarterly financial performance announcement. It is not a comprehensive Annual Report (10-K) or a full Interim Report (IR), but rather the initial release of the period's results. Q2 2016
2016-07-13 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is titled "Chiffre d'affaires du deuxième trimestre 2016" (Revenue for the second quarter of 2016) and presents detailed, non-audited financial figures (Compte de résultat) for Q2 2016 and H1 2016. It discusses revenue recognition from licensing agreements and milestones, and mentions upcoming financial communication (results for the first half of 2016 on August 31, 2016). This content structure—a press release announcing specific, periodic financial results (quarterly revenue) but not the full, comprehensive annual filing (10-K) or a formal half-year report (IR)—is characteristic of an Earnings Release (ER). It provides key financial highlights for the period. Q2 2016
2016-07-13 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Share Issue/Capital Change Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" (Semi-annual balance sheet of the liquidity contract with the brokerage firm Gilbert Dupont) and provides an update on the cash and share balance in the liquidity account as of June 30, 2016, comparing it to the previous annual balance (December 31, 2015). This is a periodic report detailing the status of a specific financial arrangement (liquidity contract/market making). Since it is a semi-annual report focusing on financial/contractual status, it aligns best with the 'Interim / Quarterly Report' (IR) category, as it covers a period shorter than a year and provides detailed financial/contractual figures, rather than just a brief announcement (RPA/RNS) or a full annual report (10-K). It is not a standard earnings release (ER) or a general audit report (AR).
2016-07-08 French
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 95% confidence The document is a press release dated July 6, 2016, announcing positive results from a Phase I/II clinical trial of NBTXR3 for Head & Neck Cancer. It details trial design, safety data, tumor response, and next steps for clinical development, including preparing a registration clinical plan. This format—a formal announcement of periodic operational/clinical results, often including key financial/operational highlights but not the full statutory report—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses heavily on clinical trial results and future development plans rather than just quarterly financial figures, it aligns best with the 'Earnings Release' category, which often encompasses significant operational updates released concurrently with or instead of a formal earnings report, especially for clinical-stage biotech companies. It is not a full 10-K, an Audit Report (AR), or a simple Report Publication Announcement (RPA) as it contains substantial substantive data and commentary, not just a notice of publication. Given the context of a clinical-stage company, this announcement of trial success and future registration plans functions as their primary periodic update.
2016-07-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated July 6, 2016, announcing positive Phase I/II trial results for the product NBTXR3 in head and neck cancers. It details clinical trial design, safety data, tumor response rates, and outlines next steps for clinical development, including plans for regulatory registration in Europe and the US. This content—a detailed announcement of clinical trial results and future development plans, often issued by biotech/pharma companies—is characteristic of an Earnings Release (ER) or a specific clinical update. Since it focuses heavily on clinical data and progress rather than just summary financial figures (which would suggest ER), and it is not a formal regulatory filing like a 10-K or a full quarterly report (IR), it best fits the category for initial results announcements. Given the depth of the clinical data presented, it is more substantial than a typical 'Earnings Release' (ER) which usually focuses on financial metrics. However, in the context of the provided definitions, this is a detailed announcement of clinical progress, which often accompanies or substitutes for a standard earnings report in the biotech sector, or it could be classified as a general announcement. Since it is a detailed announcement of trial results and future strategy, it strongly aligns with the purpose of an Earnings Release (ER) or an Investor Presentation (IP). As it is presented as a news release detailing results and future strategy, ER is the most appropriate fit among the options for a significant corporate update, although it lacks explicit financial earnings figures. If it were purely a presentation deck, IP would fit, but this is a text release. Given the focus on trial outcomes and next steps, ER is the closest fit for a major corporate update announcement. FY 2016
2016-07-06 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of June 30, 2016. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement in France, often related to major shareholding notifications or capital structure updates. Given the options, this filing most closely aligns with reporting changes in significant share ownership or capital structure. Since it is a monthly update on the total number of shares and voting rights, it fits best under Major Shareholding Notification (MRQ) or potentially Share Issue/Capital Change (SHA). However, the specific nature of reporting the total voting rights count monthly is a key indicator for filings related to ownership thresholds or capital structure transparency. Because it is a formal, periodic disclosure about the capital structure and voting rights, and not a general regulatory announcement (RNS) or a dividend notice (DIV), MRQ (Major Shareholding Notification) is the most appropriate fit, as these reports often accompany or precede threshold crossings, or are required periodically regardless of crossings. It is a specific regulatory disclosure about the capital base.
2016-07-05 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.